BioSpace News Archive

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced the first patient has been dosed in the Phase 1/2 ASPEN-02 study evaluating the combination of ALX148, a next-generation CD47 blocker, with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome.

Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time

Business combination transaction with Arya Sciences Acquisition Corp II, a special purpose acquisition company sponsored by Perceptive Advisors, completed on October 27, 2020

- Multiple milestones expected in the Fourth Quarter from the Company’s ARC pipeline including Phase 3 data from the pivotal SIERRA trial for Iomab-B and Actimab-A combination trials with CLAG-M and venetoclax - Ad hoc interim analysis from SIERRA to be completed by year end

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Thursday, November 5, 2020, to discuss the Company’s financial results and provide a corporate update. The conference call may be

Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2020 financial results and provide a corporate update on Wednesday, November 4, 2020 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Wednesday, November 4, 2020 @ 4:30 p.m. Eastern/1:30 p.m. P

Finch Therapeutics Presents Data from Its Positive PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences PRISM3 data presented at the annual meetings of the United European Gastroenterology and the American College of Gastroenterology Late-breaker oral presentations expand on previously announced positive topline data showing that CP101 met the primary efficacy endpoint with statistically significant improv

Only HER2-directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for previously treated patients in this setting

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter of 2020 and provide a corporate update at 4:30 p.m. ET on November 4, 2020. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 5179918. A live web

Rapid-result testing enables symptomatic patients who test negative for COVID-19 to access testing and care for influenza and other seasonal illnesses at MinuteClinic